Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative QL1706 (Iparomlimab/Tuvonralimab) in Resectable NSCLC
NCT06897046Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2025
- Primary completion
- Feb 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jul 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06897046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897046.